CA-ALKIRA,-INC.
Network Cloud pioneer Alkira® today announced a close collaboration with the Microsoft for Startups program, a select group of emerging businesses hand-picked by Microsoft for the benefits they offer to Microsoft Azure customers in their journey to the cloud. The select start-ups receive growth partnership and ecosystem support from Microsoft including access to technical, sales and marketing opportunities and leadership. Alkira also announced that the Alkira Cloud Services Exchange (CSX) – the core of the company’s Network Cloud platform – is now available on the Azure Marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005521/en/
The Alkira Network Cloud platform which reduces the time, cost and complexity of connectivity cloud environments, provides Azure customers with increased performance, manageability and security when deploying Windows workloads in the Azure cloud. Microsoft Azure customers can access Alkira’s solution in Azure, or in a multi-cloud network alongside other best-of-breed products in the Azure Marketplace.
Benefitting from the underlying power of Azure, Alkira CSX is delivered as a secure cloud networking infrastructure as-a-service that dynamically scales according to customers’ needs and reduces the time taken to deploy cloud networks from months to minutes.
Amir Khan, Chief Executive Officer and Founder of Alkira, said: “The time, cost and complexity of building networks in the cloud with end-to-end security and management visibility are major challenges holding back digital transformation. Our service was developed to help businesses overcome the trade-offs, complexity and long lead times associated with cloud networking. The Alkira Network Cloud platform accelerates the deployment and simplifies the management of cloud workloads, leaving customers free to focus on the objectives of their business. We’re excited to be deepening our relationship with Microsoft through the Microsoft for Startups program and to be able to offer those benefits to the growing number of organizations seeking transformational solutions from the Azure Marketplace.”
Jeff Ma, General Manager of Microsoft for Startups, commented: “Our start-up program gives new businesses access to the incredible resources of Microsoft and helps to bring the benefits of exciting new technologies like Alkira’s Network Cloud platform to Microsoft’s Azure customers. Alkira’s platform provides a powerful and flexible set of capabilities to leverage the power of Azure to deploy fully featured cloud networks.”
Mamoon Hamid, Partner at Kleiner Perkins added: “It’s time for the network to join the cloud era, and Alkira’s Cloud Networking Infrastructure as-a-Service provides customers a secure, simplified path to the Microsoft Azure cloud. Microsoft is progressively offering companies like Alkira the opportunity to help Azure customers on their cloud journey, and we're already seeing it unlock value for everyone involved."
Brad Casemore, Research Vice President, Datacenter Networks at IDC said: “IDC finds that enterprises are gaining greater appreciation of how modern infrastructure can support strategic cloud objectives such as business agility, application experience, robust security. That said, while enterprise architects want to help their organizations achieve greater business agility through the migration of workloads to cloud, they also want to ensure that the transition doesn’t entail compromises to operational control and management. Alkira’s Network Cloud platform addresses these requirements by helping organizations and their architects reconcile the business benefits of cloud with the need for effective control.”
Microsoft customers who access Alkira’s Network Cloud through Azure Marketplace benefit from reduced procurement overheads, simplified billing and quicker deployment, as well as the assurance of Microsoft certification.
For more information:
- Read Amir Khan’s blog on teaming with Microsoft
- Download an Alkira in Azure Cloud white paper
About Alkira
Alkira® developed the Network Cloud which enables Enterprises to build and deploy a global unified Cloud Network Infrastructure as-a-Service (CNaaS) that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira Cloud Services Exchange™ (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of Integrated Solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® is a registered trademark and Alkira Cloud Services Exchange™ is a trademark of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005521/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom